natgillin/translations-raw huggingface dataset:
The method of any one of claims 6 to 9, further comprising increasing the mobile phone account of the user (102) to include a balance for payment of goods or services (105) from a merchant (104). 
Metoda prema bilo kojem od zahtjeva 5 do 7, dalje sadržeći povećanje salda računa mobilnog telefona korisnika (102) koje je dovoljno za plaćanje Toba ili usluga (105) od trgovca (104).
The method of claim 1 wherein the organ is a solid organ. The method of claim 6, wherein the solid organ is selected from the group consisting of kidney, pancreas, intestine, heart, lung, and liver. 
C1-INH namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je organ čvrsti organ, gdje se čvrsti organ može birati iz skupine koju čine bubreg, gušterača, crijeva, srce, pluća, jetra, te njihova kombinacija.
A method as claimed in claim 15 in which the subject takes additional clear fluid after one or both of the first and second colon cleansing solutions. 
Pripravak ili otopina namijenjeni upotrebi u postupku čišćenja debelog crijeva subjekta u skladu s patentnim zahtjevom 19, naznačeni time što subjekt uzima dodatnu bistru tekućinu nakon jedne ili obje od prve i druge otopine za čišćenje debelog crijeva.
Optionally, the product can then be sieved followed by a recycling of the out-of-range material. 
Opcijski, proizvod se tada može prosijati, a čestice neprihvatljive veličine reciklirati.
The method according to claim 1, wherein industrial byproducts and process dusts are used as correcting agents for adjustment of an amount of CaO, Al2O3(Fe7O3), SiO2 and SO3 and ratios by weight of CaO/Al2O3(Fe7O3) and CaO/SiO2 in the raw meal mixture. 
Postupak sukladno barem jednom od zahtjeva 1 do 5, naznačen time što industrijski nusproizvodi i procesna praškasta sredstva se koriste kao sredstva za ispravljanje za sirove smjese obroka.
Containers produced by the process of the present invention, however, typically having the same small amount of heat induced crystallinity and mobile amorphous phase but exhibit a high percentage of the rigid amorphous phase, i.e., 60% or greater. 
PET posuda iz patentnog zahtjeva 1 gdje PET posuda ima toplinom induciranu kristalnost od oko 20%, rigidnu amorfnu fazu oko 60% i mobilnu amorfnu fazu oko 20%.
Compounds according to claim 1 or 2 selected from: 
Spojevi u skladu sa zahtjevom 1 ili 2, naznačeni time, da su izabrani iz slijedeće skupine:
A combination according to claim 1 wherein the anti-alpha-4 integrin antibody is a humanized antibody. 
Kombinacija u skladu sa zahtjevom 1, naznačena time, da anti-alfa-4 integrin antitijelo je humanizirano antitijelo.
The tubular member 4 and the flushing unit 5 together define a first interior guiding passage 10 extending longitudinally from the proximal open end 8 of the flushing unit to the distal open end 7 of the tubular member for sheathing a part of the endoscopic instrument 2. 
Cijevni element 4 i jedinica za ispiranje 5 zajedno određuju prvi unutarnji prolaz za vođenje 10 koji se prostire uzdužno od bližeg otvorenog kraja 8 jedinice za ispiranje do udaljenijeg otvorenog kraja 7 cijevnog elementa za omatanje dijela endoskopskog instrumenta 2.
The compound of Paragraph 42, wherein R43 and R44, taken together with the carbon atoms to which they are attached, form a C5-C8 cycloalkenyl or a C5-C8 aryl. 
Spoj prema zahtjevu 36, pri čemu R43 i Ra, uzeti zajedno sa ugljikovim atomima za koje su vezani čine Cs-Cg cikloalkenil ili Cs-Cg aril.
FIELD OF THE INVENTION The present invention relates to a method for the purification of non-immunoglobulin proteins comprising one or more immunoglobulin-like (Ig-like) domain. 
Ovaj izum odnosi se na postupak za pročišćavanje ne-imunoglobulinskog proteina koji sadržava jednu ili više domena sličnih imunoglobulinskoj domeni (1g-sličnu domenu).
A process according to Claim 4, wherein LG' is p-nitrophenoxide. 
Proces prema patentnom zahtjevu 7, gdje A je anhidriran.
15 a and 16 a respectively show the status before the water pressure acts on the sealing material 8 . 
Slike 15a odnosno 16a prikazuju položaj prije nego što tlak vode djeluje na materijal za brtvljenje 8.
An antibody of any one of claims 1 to 14 and/or a conjugate of claim 16 for use in a method of inhibiting growth and/or killing of a cell expressing CLD 18. 
Protutijelo iz bilo kojeg od patentnih zahtjeva 1 do 5 i/ili konjugat iz patentnog zahtjeva 7 za uporabu u metodi za inhibiranje rasta i/ili ubijanje stanice koja izražava CLD18A2.
A process for preparing a pharmaceutical comprising one or more of the compounds as claimed in one or more of claims 1 to 4, which comprises mixing the active compound with a pharmaceutically suitable carrier and bringing this mixture into a form suitable for administration. 
Postupak pripravljanja farmaceutskog pripravka koji sadrži jedan ili više spojeva formule I u skladu s jednim ili više patentnih zahtjeva 1 do 23, koji se sastoji u miješanju aktivnog spoja s farmaceutski pogodnom podlogom, te u dovođenju te smjese u oblik pogodan za primjenu
A further embodiment of the present invention relates to compounds of the formula (Ia″), where the compounds of the formula (Ia″) are compounds of the formula (I-T3) 
Spojevi prema zahtjevu 1, naznačeni time da spojevi s formulom (1a") su spojevi s formulom (I-T3) a ONOOS R11
Advantageously, the compensation cylinder is disposed in a wall of the housing in a valve of this type according to the invention. 
Ventil (1) u skladu s prethodnim patentnim zahtjevom, karakteriziran na način da je kompenzacijski cilindar (25) postavljen u stijenku kućišta (2).
In one aspect, the teaching relates to a pharmaceutical composition comprising an agent which recognizes a tumor-associated antigen identified according to the teaching or a nucleic acid coding for the tumor-associated antigen and which is preferably selective for cells which have expression or abnormal expression of a tumor-associated antigen identified according to the teaching. 
Farmaceutska kompozicija prema patentnom zahtjevu 1 ili 2 za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 1, gdje je antitijelo spojeno za terapeutsko ili dijagnostičko sredstvo.
Method according to anyone of claims 1 to 8, wherein the concentrator (C) determines whether a remote meter (RM) is enabled to perform the operation of transmitting an amount (L) of said periodically measured and stored consumption related data (MV1, MV2... 
Metoda prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu sabirnik (C) određuje je li daljinskom brojaču (RM) omogućeno provoditi operacije prijenosa količine (L) periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju (MVI1, MV2...
The use of Claim 14 or antibody for use according to Claim 12, wherein the Cadherin-11-mediated disorder is fibrosis, or wherein the Cadherin-11-mediated disorder is cancer. 
Upotreba prema zahtjevu 14 ili protutijelo prema zahtjevu 12, naznačena time da poremećaj koji je povezan s proteinom kadherinom-11 je fibroza, ili pri čemu poremećaj koji povezan s proteinom kadherinom-11 je rak.
In one embodiment, this invention provides a compound represented by the structure of formula VII: 
(> VI 3. Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom VII:
Speed by volume of the fluidization air was kept at 60 m3/hour in the first 15 minutes of the pelletization and later at 90 m3/hour. 
Volumna brzina zraka za fluidiziranje održavana je na 60 m'/sat tijekom prvih 15 minuta granuliranja i nakon toga na 90 mVsat.
side walls having different angles to a plane extending perpendicularly to the plane of the planar form. 
- = zakrivljene bočne zidove, i - > bočne zidove koji imaju različite kutove prema ravnini koja se proteže okomito na ravninu planarnog oblika.
By means of the conditioning steps according to the characterizing portion of claim 1, a cutting of the veneers results that is particularly smooth, and that has a high quality, which, also for a low thickness of the veneers, does not cause cracks. 
Pomoću faza za kondicioniranje, koje su u skladu s karakterističnim dijelom patentnog zahtjeva 1, rezanje furnira ima za posljedicu da je on vrlo gladak, i da ima visoku kvalitetu, koja također vrijedi i za furnir koji ima malu debljinu, i da se ne stvaraju pukotine.
A compound according to claim 1, wherein each of R1 and R′1, or said fused ring structure formed thereby, is optionally substituted by at least one substituent selected from the group c′: fluorine and chlorine atoms; hydroxyl groups; linear and branched alkyl, alkylthio, hydroxyalkyl, and fluoroalkyl groups; linear and branched alkoxyl groups; trifluoromethyl and trifluoromethoxyl groups; —CN groups; alkylcarbonyl groups; and alkylsulphonyl groups, wherein any alkyl component has from 1 to 4 carbon atoms, and wherein, when there is more than one substituent, then each said substituent is the same or different. 
Spoj prema zahtjevu 3 ili 4, naznačen time da svaki R, 1 R',, ili navedena kondenzirana prstenasta struktura koja je tako formirana, proizvoljno je supstituirana sa barem jednim supstituentom odabranim iz skupine c': atomima fluora ili klora, hidroksilom, ravnim i razgranatim alkilom, alkiltio, hidroksialkilom, te fluoroalkilnim skupinama; ravnim i razgranatim alkoksil skupinama; trifluorometilom; trifluorometoksilom; -CN; alkilkarbonilnim skupinama; alkilsulfonilnim skupinama, te bilo koja alkilna komponenta ima od 1 do 4 atoma ugljika, te pri čemu, kada postoji više od jednog supstituenta, tada je svaki navedeni supstituent isti ili različit.
MgO 0 to 25% by weight, preferably 2 to 15% by weight, and still more preferably 5 to 10% by weight relative to the total quantity of clinker/cement, with the amount of the contents adding up to 100%. 
Vezivo sukladno zahtjevu 3, naznačeno time što sadrži klinker kalcijevog sulfoaluminata u količimi opsega od 10 do 90 % mase, poželjno 20 do 70 % mase i ternesit klinker u količini opsega od 10 do 90 % mase, poželjno 30 do 80 % mase, pri čemu sve komponente veziva iznose do 100 %.
The pharmaceutical composition according to any one of Claims 2 to 6, wherein the suppressor of collagen production by collagen-producing cells is selected from the group consisting of a TGFB inhibitor, HGF or a substance promoting the production thereof, a PPARY ligand, an angiotensin inhibitor, a PDGF inhibitor, relaxin or a substance promoting the production thereof, a substance that inhibits the production and secretion of an extracellular matrix component, a cell activity suppressor, a cell growth suppressor, and an apoptosis-inducing substance. 
Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što se supresor proizvodnje kolagena u stanicama koje proizvode kolagen bira iz skupine koju čine inhibitor TGFB, HGF ili tvar koja potiče njegovu proizvodnju, PPARY ligand, angiotenzinski inhibitor, PDGF inhibitor, relaksin ili tvar koja potiče njegovu proizvodnju, tvar koja inhibira proizvodnju i izlučivanje komponente izvanstaničnog matriksa, supresor stanične aktivnosti, supresor staničnog rasta i tvar koja potiče apoptozu.
A method as claimed in any of Claims 1 to 15 wherein step (c) involves the use of FRET. 
Metoda iz Zahtjeva 1-15 naznačena time da korak (c) obuhvaća primjenu rezonantnog prijenosa energije fluorescencije (FRET).
In another embodiment, the human IgG4 constant region comprises the amino acid sequence of SEQ ID NO: 12, and the human k light chain constant region comprises the amino acid sequence of SEQ ID NO: 13. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 8, naznačen time što humana IgG4 konstantna regija sadrži aminokiselinsku sekvencu iz SEQ ID NO: 12, i humana x konstantna regija lakog lanca sadrži aminokiselinsku sekvencu iz SEQ ID NO: 13.
The process according to claim 1, wherein the medium further comprises amino acids selected from Alanine, Arginine, Aspartic Acid, Cysteine, Glutamic Acid, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenyalanine, Proline, Serine, Tryptophan, Tyrosine, Threonine, and Valine, but no Glutamine. 
Proces u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da medij nadalje sadrži aminokiseline odabrane između alanina, arginina, aspartatske kiseline, cisteina, glutaminske kiseline, glicina, histidina, izoleucina, leucina, lizina, metionina, fenilalanina, prolina, serina, triptofana, tirozina, treonina i valina, ali ne i glutamin.
16, 2011, all of which are incorporated herein by reference in their entirety. 
(31) Broj prve prijave: PCT/NL2011/050437 (32) Datum podnošenja prve prijave: 16.06.2011.
An inhibitor of IL-6 activity which is an antibody or functionally-active fragment, which antibody or functionally-active fragment binds to IL-6 or to the IL-6R and interferes with IL-6R-ligand interaction or binds to IL-6 and interferes with the IL-6-gp130 interaction, for use in the treatment and/or prophylaxis of glomerulonephritis associated with a vasculitic disorder. 
Inhibitor IL-6 aktivnosti koji je antitijelo ili funkcionalno aktivni fragment, koje antitijelo ili funkcionalno aktivni fragment se vezuje za IL-6 ili za IL-6R 1 utječe na IL-6R-ligand interakciju ili se vezuje za IL-6 i utječe na IL-6- £p130 interakciju, za upotrebu u liječenju i/ili profilaksi glomerulonefritisa povezanog sa vaskulitis poremećajem.
The pharmaceutical dosage form of any one of claims 1 to 8, wherein the lower limit of 14-hydroxycodeinone is 5 ppm, 2 ppm, 1 ppm, 0.5 ppm or 0.25 ppm. The pharmaceutical dosage form of any one of claims 1 to 10 which is obtainable by a process comprising the steps reacting an oxycodone base composition comprising 8,14-dihydroxy-7,8-dihydrocodeinone with hydrochloric acid, whereby 8,14-dihydroxy-7,8-dihydrocodeinone is dehydrated to 14-hydroxycodeinone during salt formation, and under reducing conditions so as to convert the 14-hydroxycodeinone to oxycodone, thus providing an oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less than 25 ppm, and 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 5 ppm. Postupak prema bilo kojem zahtjevu od 1 do 4, naznačen time da je sastav oksikodon hidroklorida koji ima razinu 14-hidroksikodeinona manju od 25 ppm naknadno hidrogeniran kako bi se dodatno smanjila količina 14-hidroksikodeinona. Postupak prema bilo kojem zahtjevu od 1 do 5, naznačen time da postupak nadalje sadrži povrat dobivenog sastava oksikodon hidroklorida koji ima razinu 14-hidroksikodeinona manju od 25 ppm.
An example of a haematological malignancy which can be treated in accordance with the present invention is acute lymphoblastic leukaemia (ALL). The scope of the present invention however is not restricted to these specific examples. In one embodiment, the present invention provides a compound of formula (I) or (II) for use in the treatment of breast cancer, gastric cancer or bladder cancer, particularly breast cancer or gastric cancer, especially breast cancer. 
Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je čvrsti tumor kod ljudi koji eksprimira HER2 rak dojke, rak želuca, rak mokraćnog mjehura, rak jajnika, rak pluća, rak prostate, rak gušterače, kolorektalni rak, rak pločastih stanica glave i vrata ili osteosarkom. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je čvrsti tumor kod ljudi koji eksprimira HER2 rak dojke ili rak želuca.
the single nucleotide polymorphism marker having a C at the position corresponding to position 92 in SEQ ID NO:6, 
marker polimorfizma jednostrukog nukleotida koji ima C na položaju koji odgovara položaju 92 u SEQ ID NO:6,
The peptide according to Claim 3, wherein said fusion protein comprises the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s patentnim zahtjevom 3, pri čemu navedeni fuzijski protein sadrži N-terminalne aminokiseline HLA-DR varijantnog lanca vezanog za antigene (li).
wherein; R1-R2 are independently selected from hydrogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, and C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl or R1 and R2 together with the nitrogen form a 4-7 membered ring containing zero or one double bond, optionally said ring in addition to said nitrogen comprises one further heteroatom selected from nitrogen, oxygen and sulphur; 
R* u kojem je atom sumpora pričvršćen na indol preko ugljikovog prstena indola i u kojem - R-R? se nezavisno biraju iz vodika, C,.4-alk(en/in)il, C;_.g-cikloalk(en)il i C3 g-cikloalk(en), ili R!iR? zajedno s dušikom tvore 4-7-člani prsten koji sadrži nula ili jednu dvostruku svezu a, opcionalno, rečeni prsten, uz rečeni
in which the bond via which the group is connected to the group A is depicted by the line starting at the nitrogen atom. 
Q u kojoj je veza preko koje je ta skupina vezana na skupinu A prikazana linijom koja polazi od atoma dušika.
The temperature of drying was raised to 30 - 35 °C when LOD was 5.8 %. 
Temperatura sušenja podignuta je na 30-35 *C kada je LOD bio 5,1 %.
This residue was treated with petroleum ether (30-40 °C) and the resulting suspended orange solid collected by filtration. The solid was dissolved in ethyl acetate: hexane (15:85) and purified by column chromatography (silica, gradient ethyl acetate: hexane (15:85) to ethyl acetate). 
Ostatak se tretira petrolej eterom (30-40 "C) i rezultirajuća suspenzirana narančasta krutina se sakupi filtriranjem.Krutina se otopi u smjesi etil acetat: heksan (15:85) 1 pročisti se kromatografijom na koloni (silicij, gradijent etil acetat: heksan (15:85) do etil acetata).
The compound of claim 1 wherein R1 is methoxy. 
Spoj prema patentnom zahtjevu 1 naznačen time što je R, jednako metoksi.
For sanitization, the column was flushed with at least 3 BV of NaOH 0.5 M, incubated for 1 hour, and then the column was rinsed with 3 BV of purified water. 
Za sterilizaciju, kolona je bila oprana s najmanje 3 BV 0.5 M NaOH, inkubirana 1 sat, a nakon toga ista je bila oprana s 3 BV pročišćene vode.
The pharmaceutical composition of claim 12, wherein the composition comprises 500-5,000 ug/mL of sodium hyaluronate or hyaluronic acid. 
Farmaceutski oblik za uporabu prema zahtjevu 5, gdje farmaceutski oblik sadrži natrijev hijaluronat ili hijaluronsku kiselinu u terapijski učinkovitoj koncentraciji od 500-5,000 ug/mL.
In a further embodiment the dispenser is provided with an outflow end located transversely to the relatively rigid line section, with a shut-off valve that during use interacts with the dispensing head and that can be opened and closed by operating the dispensing head. 
U daljoj izvedbi djelitelj ima ostvaren s izlazni kraj koji je smješten poprečno na relativno čvrsti dio cijevi, s ventilom za zatvaranjem koji za vrijeme upotrebe međudjeluje s glavom raspršivača i koji se može otvoriti ili zatvoriti djelovanjem na glavu raspršivača.
In a further embodiment, the present invention also relates to use of a compound of formula I for the preparation of a medicament for the treatment of social phobia. 
U daljnjoj verziji, ovaj izum se odnosi i na uporabu spoja formule I za pripravu lijeka za liječenje socijalne fobije.
The analytical fluorescence based assay of claim 11, wherein said cell suspension is a suspension of non-adhering cells. 
Uporaba prema zahtjevu 11, gdje je suspenzija stanica suspenzija ne-prijanjajućih stanica.
said composition is formulated in a colon targeted drug delivery system, with the colon targeted delivery system being a matrix-within-matrix system, which is a controlled release formulation of a hydrophilic first matrix comprising a lipophilic phase and an amphiphilic phase, wherein the lipophilic phase and the amphiphilic phase are in a second matrix together and said second matrix is dispersed throughout the hydrophilic first matrix, and wherein the compound is at least partially incorporated into the amphiphilic phase. 
(b) navedena smjesa je formulirana u sistemu za dostavu lijeka koji cilja debelo crijevo, sistem za dostavu lijeka koji cilja debelo crijevo je sistem "matriks u matriksu", što je formulacija sa kontroliranim oslobađanjem načinjena od hidrofilnog prvog matriksa koji sadrži lipofilnu fazu i amfifilnu fazu, pri čemu su lipofilna faza 1 amfifilna faza zajedno u drugom matriksu i navedeni drugi matriks je disperziran kroz hidrofilni prvi matriks, i gdje je spoj bar dijelom inkorporiran u amfifilnu fazu.
The propeller arrangement according to claim 3, characterised in that the diameter of the circular path of the at least one rotor fin is less than 35% of the diameter of the propeller. 
Sklop propelera prema zahtjevu 3, naznačen time da je barem jedna lopatica statora (20) smještena na glavčini propelera (11) propelera (10) i čvrsto je spojena na njega.
identifying said sensitive patient for treatment with a WEE1 inhibitor, wherein the level of PKMYT1 from said patient sample is below that of the control sample; and administering a WEE1 inhibitor to the sensitive patient. 
(c) identificiranje navedenog osjetljivog pacijenta za liječenje inhibitorom WEE], gdje je nivo PEMYTI1 iz navedenog pacijentovog uzorka ispod onog u kontrolnom uzorku; i (d) primjenu inhibitora WEE1 kod osjetljivog pacijenta.
In this embodiment, for example, the duration of the active OFDM symbol may be 448 µs (at 4k FFT mode for 8MHz bandwidth CATV systems) or 597 µs (at 4k FFT mode for 6MHz bandwidth CATV systems). 
Postupak prema zahtjevu 1, gdje je vrijednost aktivnog OFDM polja trajanja simbola jedna od 448 us na 4k brzih Fourierovih transformacija (FFT), mod za prijenosni sustav od 8 MHz širine pojasa 1 448 x (8/6) us na 4k FFT mod za prijenosni sustav od 6 MHz širine pojasa.
represents hydrogen or methyl, 
R- predstavlja vodik ili metil,
The process according to claim 1, further comprising in step a), adding auxiliaries which improve the processability of the mixture produced, wherein the auxiliaries are selected from the group consisting of silicas, silicates, aluminates, and aluminosilicates. 
Postupak prema zahtjevu 1, naznačen time da se, osim spoja koji sadrži ugljik, u oksidnu krutu tvar u koraku a) dodaju daljnje pomoćne tvari koje poboljšavaju procesabilnost proizvedene smjese, poželjno pirogeni silicijev dioksid, silikati, aluminati i aluminosilikati.
Generally, these salts are, for example, prepared by means of the reaction of free acidic or basic forms of these compounds in a stoichiometric amount with a corresponding base or acid in water or an organic dissolvent or a mixture of both. 
Općenito, te soli su proizvedene, na primjer, reakcijom slobodnih kiselih ili bazičnih oblika tih spojeva u stehiometrijskoj količini s odgovarajućom bazom ili kiselinom u vodi ili u organskom otapalu ili u mješavini obojeg.
The compound of claim 1 selected from the group consisting of: 
Spoj, naznačen time, da je odabran iz skupine koju čine:
With regard to the screen 9 and the keyboard 8, these have been placed at the wall 23 of the cabinet 2 so as not to take too much room from the refrigerated space 21; the screen 9 may advantageously be of the flat type; the keyboard 8 may advantageously be of the flat type; the screen 9 and the keyboard 8 could also be incorporated in a “touch screen”; in FIG. 1, the keyboard 8 protrudes a little (for example by 10 cm) with respect to the flat surface of the wall 23 of the cabinet 2; alternatively, the apparatus 1 may be produced in such a manner that neither the screen 9 nor the keyboard 8 protrude in the slightest from the wall 23 of the cabinet 2 . In FIG. 
Å to se tiče ekrana 9 i tipkovnice 8, oni su smješteni na stijenku 2 ormarića 23 tako da ne zauzimaju suviše od prostora koji je namijenjen da bude prostor za hlađenje 21; povoljno je da je ekran 9 takve vrste da ima ravnu plohu ekrana; povoljno je da je tipkovnica 8 također takve vrsta da ima ravnu plohu; ekran 9 i tipkovnica 8 mogu također biti zajedno ugrađeni kao "dodirni ekran"; na slici 1 je tipkovnica 8 malo izbočena (na primjer do 10 cm) u odnosu na ravnu površinu stijenke 23 ormarića 2; alternativno može ovaj uređaj 1 biti izveden na takav način da ni ekran 9 ni tipkovnica 8 nisu niti malo izbočeni iz stijenke 23 ormarića 2.